Prokarium Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.prokarium.com
A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
Phase 1
Recruiting
- Conditions
- Non Muscle Invasive Bladder CancerNMIBCHigh Risk NMIBC
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Prokarium Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT06181266
- Locations
- 🇺🇸
Michael G. Oefelein Clinical Trials, Bakersfield, California, United States
🇺🇸Duke Health-Duke Cancer Center, Durham, North Carolina, United States
🇺🇸Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, United States
Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine
Phase 1
Completed
- Conditions
- Enteric Fever
- Interventions
- Biological: PlaceboBiological: ZH9PA and ZH9Biological: ZH9PA
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- Prokarium Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT04349553
- Locations
- 🇬🇧
Simbec Research, Merthyr Tydfil, Wales, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath